Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016
Published Oct 29, 2016
62 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections Pipeline Review, H2 2016, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 4, 2, 3, 1 and 6 respectively for Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively for Haemophilus influenzae Type B Infections.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide

  
Source:
Document ID
GMDHC8617IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Haemophilus influenzae Type B Infections Overview81
Therapeutics Development92
  Pipeline Products for Haemophilus influenzae Type B Infections Overview91
  Pipeline Products for Haemophilus influenzae Type B Infections Comparative Analysis101
Haemophilus influenzae Type B Infections Therapeutics under Development by Companies111
Haemophilus influenzae Type B Infections Therapeutics under Investigation by Universities/Institutes121
Haemophilus influenzae Type B Infections Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Haemophilus influenzae Type B Infections Products under Development by Companies162
Haemophilus influenzae Type B Infections Products under Investigation by Universities/Institutes181
Haemophilus influenzae Type B Infections Companies Involved in Therapeutics Development1910
  Beijing Minhai Biotechnology Co., Ltd191
  Biological E. Limited201
  Daiichi Sankyo Company, Limited211
  Indian Immunologicals Limited221
  Kaketsuken K.K.231
  LG Life Science LTD.241
  Panacea Biotec Limited251
  Sanofi Pasteur SA261
  Sinovac Biotech Ltd.271
  Zydus Cadila Healthcare Limited281
Haemophilus influenzae Type B Infections Therapeutics Assessment298
  Assessment by Monotherapy Products291
  Assessment by Combination Products301
  Assessment by Target312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3722
  (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile371
  (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile381
  (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile391
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile401
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile411
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile421
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile431
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile441
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile451
  (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile462
  (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine Drug Profile481
  (meningococcal + Haemophilus influenzae [serotype B]) vaccine Drug Profile491
  Eupenta Drug Profile501
  haemophilus influenzae B vaccine Drug Profile511
  Haemophilus influenzae B vaccine Drug Profile521
  Haemophilus influenzae B vaccine Drug Profile531
  hemophilus influenza [serotype B] vaccine Drug Profile541
  KD-370 Drug Profile551
  LT-Hib Drug Profile561
  NU-300 Drug Profile571
  VN-0105 Drug Profile581
Haemophilus influenzae Type B Infections Dormant Projects592
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Haemophilus-influenzae-Type-B-Infections-Pipeline-Review-H2-2016-2088-16732>
  
APA:
Global Markets Direct - Market Research. (2016). Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Haemophilus-influenzae-Type-B-Infections-Pipeline-Review-H2-2016-2088-16732>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.